Fesoterodine Fumarate Tablet, Film Coated, Extended Release
Product Images NDC 68382-479

7 FDA label images from Zydus Pharmaceuticals Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Fesoterodine Fumarate (NDC 68382-479). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (31147557 7284 42b5 Ad41 6fa7e3d37a68 01)

Image (31147557 7284 42b5 Ad41 6fa7e3d37a68 01)
Chemical structure of fesoterodine fumarate, illustrating the molecular formula with structural details of the active ingredient.*
FDA Label Image

Image (31147557 7284 42b5 Ad41 6fa7e3d37a68 02)

Image (31147557 7284 42b5 Ad41 6fa7e3d37a68 02)
A line graph showing the mean change from baseline in number of micturitions per 24 hours over 12 weeks for placebo and fesoterodine fumarate tablets at 4 mg and 8 mg doses. The x-axis represents weeks (0 to 12), and the y-axis shows mean change from baseline, with fesoterodine fumarate 8 mg having the greatest reduction.*
FDA Label Image

Feso- Image 2 (31147557 7284 42b5 Ad41 6fa7e3d37a68 03)

Feso- Image 2 (31147557 7284 42b5 Ad41 6fa7e3d37a68 03)
A line graph depicting mean change from baseline over 12 weeks in urge incontinence episodes per 24 hours among three groups: placebo (dotted line), fesoterodine fumarate 4 mg (dashed line), and fesoterodine fumarate 8 mg (solid line). The graph includes group sizes with placebo (N=211), fesoterodine 4 mg (N=199), and fesoterodine 8 mg (N=223). The y-axis shows mean change with negative values indicating reduction in episodes.*
FDA Label Image

Image (31147557 7284 42b5 Ad41 6fa7e3d37a68 04)

Image (31147557 7284 42b5 Ad41 6fa7e3d37a68 04)
Line graph showing mean change from baseline in the number of micturitions per 24 hours over 12 weeks. It compares placebo, fesoterodine fumarate 4 mg, and fesoterodine fumarate 8 mg, with time in weeks on the x-axis and mean change from baseline on the y-axis.*
FDA Label Image

Image (31147557 7284 42b5 Ad41 6fa7e3d37a68 05)

Image (31147557 7284 42b5 Ad41 6fa7e3d37a68 05)
A line graph depicting the mean change from baseline in urge incontinence episodes per 24 hours over a 12-week period. It compares placebo (dotted line with circles) and fesoterodine fumarate tablets, extended release, at 4 mg (dashed line with triangles) and 8 mg (solid line with squares). The graph shows data points at weeks 0, 2, 8, and 12, illustrating treatment effects over time.*
FDA Label Image

Feso_4mg (31147557 7284 42b5 Ad41 6fa7e3d37a68 06)

Feso_4mg (31147557 7284 42b5 Ad41 6fa7e3d37a68 06)
Label for Fesoterodine Fumarate Extended-Release Tablets, 4 mg strength, film-coated tablets. The package contains 30 tablets and is labeled for prescription use only. The label shows the NDC 68382-479-06 and mentions Zydus Pharmaceuticals USA Inc. as the distributor and Zydus Lifesciences Ltd. as the manufacturer.*
FDA Label Image

Feso-8mg (31147557 7284 42b5 Ad41 6fa7e3d37a68 07)

Feso-8mg (31147557 7284 42b5 Ad41 6fa7e3d37a68 07)
Label for fesoterodine fumarate extended-release tablets, 8 mg strength, manufactured by Zydus Lifesciences Ltd. and distributed by Zydus Pharmaceuticals USA Inc. The label indicates the product is an oral tablet, film-coated, extended-release, with a quantity of 30 tablets per container. It includes storage instructions and a caution that the package is child-resistant, emphasizing the tablets should not be chewed, divided, or crushed.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.